ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

IMM Immupharma Plc

1.90
-0.14 (-6.86%)
03 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Immupharma Plc LSE:IMM London Ordinary Share GB0033711010 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.14 -6.86% 1.90 1.84 1.96 2.01 2.00 2.00 1,925,128 16:35:20
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Finance Services 0 -3.81M -0.0114 -1.76 6.7M
Immupharma Plc is listed in the Finance Services sector of the London Stock Exchange with ticker IMM. The last closing price for Immupharma was 2.04p. Over the last year, Immupharma shares have traded in a share price range of 0.83p to 3.78p.

Immupharma currently has 333,403,115 shares in issue. The market capitalisation of Immupharma is £6.70 million. Immupharma has a price to earnings ratio (PE ratio) of -1.76.

Immupharma Share Discussion Threads

Showing 33576 to 33598 of 39125 messages
Chat Pages: Latest  1349  1348  1347  1346  1345  1344  1343  1342  1341  1340  1339  1338  Older
DateSubjectAuthorDiscuss
13/11/2018
12:30
Boom only need another 6p to be breaking a profit
kirk 6
09/11/2018
14:57
For any one who is interested Evgen Pharma has results of 2 trials due over the next few weeks, share price is starting to rise in anticipation is up 25% already this week. Currently at 17p pre results broker target is £1.10.
spmc
08/11/2018
17:21
I took off, no buyers to continue to power it.

The trend downwards resumes, I am afraid.

KoT

king of thieves
08/11/2018
15:49
No placebo group so it will never be unequivocal....or submissable from an efficacy point of view?
nobbygnome
08/11/2018
14:32
Why can't map study be kept going until it becomes unequivocal....one way or another
kop202
08/11/2018
13:45
>> colsmith

But the worry is that they are wasting time and money. The most likely outcome of the MAP is highly equivocal results which get them no further from a regulatory point of view. So what do they do then once they have spent most of the cash. A sensible management team would have realised that they had to change their approach and go back and do a study with a proposer dose. That would require reformulation (unless you just inject a lot more frequently) and another phase II dose ranging study. IMHO that would be a much better use of shareholder funds.

nobbygnome
08/11/2018
13:29
Gabberdemon...nice photo shame about your potty mouth
kop202
07/11/2018
13:04
Thought long and hard as to whether to reply to your post.As a Pharmacist with 40 years experience I do however think I know enough to comment.Clearly we disagree, I don't have a problem with that. Every patient needs to take ownership of their own condition and medication.
chrisowen
07/11/2018
12:59
Wonder when the cash runs out again, all those lovely BoD salaries getting paid every, month with no doubt a positive spin on the last disastrous RNS to come soon, in time for Xmas/NY hope and merrymaking?
ny boy
07/11/2018
12:00
Nobby re your 33664 - thanks an interesting and clearly thought out dissertation. However, the P3 results justify IMO that getting to market for a longer term use in the so called real world is justified on the results.

I believe someone with the disease would be prepared to accept the product for treatment provided their Doctor considered it in their interest; after all with the benign side effects the risk of problems would seem minimal to not existent.

Your assessment that a larger dose is likely to be more effective may well justify further work to assess different doses - the 60 or so Q19/results and later MAP results would/should mean this is considered. Q19 will be a pivotal pointing one way or the other based on the experiences of the 60 - such as I would be prepared to continue, its improved my condition, or the alternative.

Have a nice day

colsmith
07/11/2018
10:42
Any ideas why the price rise? Quantum tunnelling? Light effects round a black hole? Or..
glennrcharles
07/11/2018
00:30
A fine short.
ken chung
07/11/2018
00:30
Any news to justify the rise or is it just lemmings and mushrooms mindlessly throwing money away as usual.
ken chung
06/11/2018
22:15
Oh dear a newly joined ADVFN member today! Why do I suspect we are about to get some dubious posts......
nobbygnome
06/11/2018
18:37
Good shares

Looking to sell at 20p.


KoT

king of thieves
06/11/2018
16:20
>> stockriser

They can inject that drug once every 13 weeks because it is a depo injection, in other words it slowly seeps out over the time period. That is not true for Lupuzor where the half-life is a couple of hours at best and it will certainly be all gone by the end of day one. They cannot even measure it in the blood even straight after the injection because the concentration is so low. That adds up to homeopathy to me.....

>> gaberdemon

I wish you all good luck for whatever is wrong with you. Lupuzor has zero side effects so I think upping the dose ten fold would not be a problem from that point of view.

nobbygnome
06/11/2018
15:51
Yea maybe the dose was too low for some but enough to give remission in others?
glennrcharles
06/11/2018
15:31
All drugs have side effects, it's a question of balance between the positives and negatives of any particular medication. However to think that the more side effects experienced is directly proportionate to the benefit received is nonsense.Looks like the dose in humans was way too low to hope to be effective though which suggests gross incompetence somewhere.
chrisowen
06/11/2018
15:30
Ok this rise is unexpected......leaky leaky??
coldspring
06/11/2018
15:27
OEX looking strong again
letmepass
06/11/2018
12:24
Haha, yes, I noticed. I have plenty outbursts, so plenty apologies at the ready. I am poorly myself, so I understand the strife involved with everything, and I understand that low doses are worthless. The disease just gets more evolved. They must up the dose, and the people tested on must not complain, they must think of a way to alleviate the side effects. The more side effects, the better the drug is working IMHO, from personal experience. Obviously, we prefer to have less, but you cant always get what you want perfectly in this life. They should find ways to manage the side effects, such as enemas and supplements, juicing and explaining to patients that they must restrict their diets and practice self control, push past the side effects, drink tons of water, perhaps take niacin to flush the blood daily. To be honest, if someone is so ill, they will not care about side effects, they will ride it out, because death is much more preferable to someone in such pain, rather to continue living. In my opinion, and through my experience.

Bacteria is very resistant, and I do hope they realise about acid fast bacilli, this is a monstrous, ever evolving, pretty much invisible, and worrying aspect of disease. If not already, they should take into consideration the old time Kiehl Neelson staining, in studies. I hope they have done this, a big picture, a much needed big picture in all aspects of medical study, could be formed, and the sudden realisation will be magnificent. I could be wrong ;-)

gabberdemon
06/11/2018
12:19
NG - Genuine Question : Depo-Provera (contraceptive injection) most commonly given in the UK lasts for 13 weeks on one injection. Why can't lupuzor have a slow effect over 28 days?
stockriser
06/11/2018
11:25
PS I am happy to act as a consultant for the company to explain all this information to them at a cheap rate of £1000 per day.
nobbygnome
Chat Pages: Latest  1349  1348  1347  1346  1345  1344  1343  1342  1341  1340  1339  1338  Older

Your Recent History

Delayed Upgrade Clock